490 related articles for article (PubMed ID: 16678077)
21. The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.
Persoons P; Vermeire S; Demyttenaere K; Fischler B; Vandenberghe J; Van Oudenhove L; Pierik M; Hlavaty T; Van Assche G; Noman M; Rutgeerts P
Aliment Pharmacol Ther; 2005 Jul; 22(2):101-10. PubMed ID: 16011668
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcomes of laparoscopic versus open ileocolic resection for Crohn's disease: follow-up of a prospective randomized trial.
Stocchi L; Milsom JW; Fazio VW
Surgery; 2008 Oct; 144(4):622-7; discussion 627-8. PubMed ID: 18847647
[TBL] [Abstract][Full Text] [Related]
23. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
Maser EA; Villela R; Silverberg MS; Greenberg GR
Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
[TBL] [Abstract][Full Text] [Related]
24. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.
Farrell RJ; Alsahli M; Jeen YT; Falchuk KR; Peppercorn MA; Michetti P
Gastroenterology; 2003 Apr; 124(4):917-24. PubMed ID: 12671888
[TBL] [Abstract][Full Text] [Related]
25. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
Atzeni F; Ardizzone S; Sarzi-Puttini P; Colombo E; Maconi G; De Portu S; Carrabba M; Bianchi Porro G
Aliment Pharmacol Ther; 2005 Sep; 22(5):453-61. PubMed ID: 16128684
[TBL] [Abstract][Full Text] [Related]
26. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
[TBL] [Abstract][Full Text] [Related]
27. The elder patient with suspected acute coronary syndromes in the emergency department.
Han JH; Lindsell CJ; Hornung RW; Lewis T; Storrow AB; Hoekstra JW; Hollander JE; Miller CD; Peacock WF; Pollack CV; Gibler WB;
Acad Emerg Med; 2007 Aug; 14(8):732-9. PubMed ID: 17567963
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic efficacy of infliximab on patients with short duration of Crohn's disease: a Japanese multicenter survey.
Matsumoto T; Iida M; Motoya S; Haruma K; Suzuki Y; Kobayashi K; Ito H; Miyata M; Kusunoki M; Chiba T; Yamamoto S; Hibi T
Dis Colon Rectum; 2008 Jun; 51(6):916-23. PubMed ID: 18322754
[TBL] [Abstract][Full Text] [Related]
29. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
[TBL] [Abstract][Full Text] [Related]
30. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients.
Kane SV; Chao J; Mulani PM
Adv Ther; 2009 Oct; 26(10):936-46. PubMed ID: 19838649
[TBL] [Abstract][Full Text] [Related]
31. Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.
Menter A; Reich K; Gottlieb AB; Bala M; Li S; Hsu MC; Guzzo C; Diels J; Gelfand JM
J Drugs Dermatol; 2008 Dec; 7(12):1137-46. PubMed ID: 19137767
[TBL] [Abstract][Full Text] [Related]
32. Corticosteroid-associated complications in elderly Crohn's disease patients.
Akerkar GA; Peppercorn MA; Hamel MB; Parker RA
Am J Gastroenterol; 1997 Mar; 92(3):461-4. PubMed ID: 9068470
[TBL] [Abstract][Full Text] [Related]
33. Surgical resection in Crohn's disease: is immunosuppressive medication associated with higher postoperative infection rates?
Canedo J; Lee SH; Pinto R; Murad-Regadas S; Rosen L; Wexner SD
Colorectal Dis; 2011 Nov; 13(11):1294-8. PubMed ID: 20969715
[TBL] [Abstract][Full Text] [Related]
34. Infliximab in the surgical management of complex fistulating anal Crohn's disease.
Talbot C; Sagar PM; Johnston MJ; Finan PJ; Burke D
Colorectal Dis; 2005 Mar; 7(2):164-8. PubMed ID: 15720356
[TBL] [Abstract][Full Text] [Related]
35. How to improve the safety of biologic therapy in Crohn's disease.
Ferkolj I
J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
[TBL] [Abstract][Full Text] [Related]
36. Low mortality in ulcerative colitis and Crohn's disease in three regional centers in England.
Farrokhyar F; Swarbrick ET; Grace RH; Hellier MD; Gent AE; Irvine EJ
Am J Gastroenterol; 2001 Feb; 96(2):501-7. PubMed ID: 11232697
[TBL] [Abstract][Full Text] [Related]
37. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
[TBL] [Abstract][Full Text] [Related]
38. Infliximab in Crohn's disease: first anniversary clinical experience.
Cohen RD; Tsang JF; Hanauer SB
Am J Gastroenterol; 2000 Dec; 95(12):3469-77. PubMed ID: 11151879
[TBL] [Abstract][Full Text] [Related]
39. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis.
Selvasekar CR; Cima RR; Larson DW; Dozois EJ; Harrington JR; Harmsen WS; Loftus EV; Sandborn WJ; Wolff BG; Pemberton JH
J Am Coll Surg; 2007 May; 204(5):956-62; discussion 962-3. PubMed ID: 17481518
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of acute respiratory distress syndrome (ARDS) in elderly patients.
Eachempati SR; Hydo LJ; Shou J; Barie PS
J Trauma; 2007 Aug; 63(2):344-50. PubMed ID: 17693834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
